The Multiple Sclerosis Association of America (MSAA) will hold a live webinar on the Affordable Care Act (ACA) for individuals with multiple sclerosis on November 19, 2013 at 8 pm Eastern Standard Time. Titled The New Insurance Marketplace and MS, this one-hour webinar will provide an understandable explanation of the new health insurance Marketplace with specific information on key areas that will significantly impact the multiple sclerosis community.
Read News ArticleCategory: Latest News
Highlights from the ECTRIMS 29th Congress International Meeting
This year’s 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) was held in Copenhagen, Denmark in October, 2013. Each year, ECTRIMS hosts the world’s largest annual international meeting devoted entirely to research and care in multiple sclerosis (MS). More than 1,500 abstracts and posters were presented at this year’s conference, providing the latest findings in MS research, treatments, symptom management, and patient care to an estimated audience of nearly 7,000 MS professionals from around the world.
Read News ArticleMSAA Debuts New Mobile Website
On October 30, 2013, the Multiple Sclerosis Association of America (MSAA) debuts a new mobile website (accessed at mymsaa.org via a mobile device) to meet the growing needs of individuals with multiple sclerosis (MS) and their care partners. The mobile website allows users to have on-the-go access to many of the resources currently available on MSAA’s desktop website. The mobile website is another example of how MSAA continues to develop initiatives to improve lives today for the entire MS community.
Read News ArticleMSAA Featured in USA Today Article
Please read this USA Today article about organizations that help people with obtaining information in regard to the new health exchanges.
Read News ArticleThe Multiple Sclerosis Association of America Launches New Website Features
The Multiple Sclerosis Association of America (MSAA) is pleased to announce new website additions including an MS Relapse Resource Center and chat feature to its award-winning website, mymsaa.org. As a leading resource for the entire multiple sclerosis (MS) community, MSAA developed these additions to provide easier access to vital information and assistance to individuals with MS, their care partners, and healthcare professionals.
Read News ArticleMy MS Manager Named One of the Best Multiple Sclerosis Mobile Apps by Healthline
MSAA is pleased to announce that Healthline.com has named MSAA’s My MS Manager™ mobile phone app as one of the top smartphone and tablet applications for the iPhone and Android platforms. Healthline selected the best MS apps based on the potential to assist individuals and their loved ones in a number of ways.
Read News ArticleRecent Reports of Adverse Events with Individuals on MS Medications – How to Interpret the Information
Two reports of adverse events have appeared in the media recently. Each referred to an individual with MS who had been taking an MS disease-modifying therapy (DMT) and later became ill or died.
Read News ArticleVaccine Safety and MS
Article summary: Published studies to date continue to affirm the safety of several vaccinations for individuals with MS. These vaccines (listed in this article) do not increase the risk of developing MS or exacerbating its symptoms. The safety of the shingles vaccine is more difficult to judge for individuals with MS, since this is a live-virus vaccine. Vaccines that use a live virus could pose a risk for individuals with compromised immune systems, resulting from an illness or a medication taken for an illness. The shingles vaccine is important for individuals 60 years and older, because the risk of developing shingles, as well as a painful long-term complication of shingles, greatly increases with age. Similar to the shingles vaccine, the yellow fever vaccine also uses a weakened, live virus. In a small study, the yellow fever vaccine was shown to increase MS disease activity. Before receiving any vaccine, individuals with MS should consult their physician to make sure that the specific vaccine and its timing is appropriate for them.
Read News ArticleShingles Overview and Vaccine Safety
Article summary: Shingles is caused by the reactivation of the varicella zoster virus (VZV), which is the same virus that causes varicella (chickenpox). The reactivation of this virus causes a painful rash with clusters of fluid-filled blisters. Postherpetic neuralgia (PHN) is the most common complication of shingles, causing chronic, sometimes excruciating pain. The shingles vaccine (Zostavax®) is recommended for use in people 60 years and older to reduce the risk of shingles. The shingles vaccine is a live, attenuated vaccine, which could be an issue for members of the MS population, as medications that may modulate or suppress the immune system could pose a risk with a live vaccine. Individuals with MS who are considering a shingles vaccine should discuss the risks and benefits with their doctor.
Read News ArticleCMSC and ACTRIMS Cooperative Meeting Highlights (2013)
The largest and most comprehensive meeting on multiple sclerosis (MS) care and research in North America took place May 29 through June 1 in Orlando, Florida, combining the 27th Annual Meeting of CMSC and the 18th Annual Meeting of ACTRIMS. This meeting is unique in that it brings together researchers and clinicians from across the spectrum of MS care, including physicians, nurses, physical and occupational therapists, psychologists, social workers, pharmacists, rehabilitation specialists, and advocacy professionals.
Read News Article